Navigation Links
NicOx Reports Results for the First Three Quarters of 2008
Date:10/22/2008

lead investigational drug which is in late phase 3 studies for the treatment of the signs and symptoms of osteoarthritis.

For the nine months ended September 30, 2008, the net loss amounted to EUR49.7 million compared to EUR13.7 million for the first nine months of 2007. On September 30, 2008, the Company's current and non-current financial instruments and cash and cash equivalents were EUR124.8 million, compared to EUR172.8 million on December 31, 2007.

Review of the consolidated financial results for the nine months ended September 30, 2008 and 2007:

Revenues

NicOx' revenues totaled EUR2.9 million for the nine months ended September 30, 2008, compared to EUR18.4 million for the nine months ended September 30, 2007. This significant decrease is explained by the fact that the Company received EUR10.0 million from Merck and EUR1.0 million from Pfizer in 2007, which was entirely recognized as revenues in the first nine months of 2007.

For the first nine months of 2008, NicOx recognized the following amounts in revenues:

- EUR0.25 million corresponding to the initial payment of

EUR5.0 million from Pfizer, as a technology exclusivity fee, following

the March 2006 agreement that granted Pfizer rights to apply NicOx'

proprietary technology in a drug discovery research program covering

the field of ophthalmology

- EUR2.1 million corresponding to the funding of the research

collaboration, pursuant to the above referenced agreement signed with

Pfizer in March 2006

- EUR0.56 million corresponding to the balance of the spreading of the

initial payment of EUR9.2 million received from Merck following the

signature of a collaboration agreement for new antihypertensive drug

candidates in March 2006

These amounts initially recorded as prepaid income were deferred over the estimated duration of NicOx' involvement in the research and developmen
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
2. NicOx Announces Departure of Damian Marron for CEO Position
3. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
4. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
5. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
6. NicOx Opens U.S. Headquarters in New Jersey
7. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
8. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
9. Amylin Pharmaceuticals Reports Third Quarter Financial Results
10. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
11. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... -- Vermillion, Inc. (Pink Sheets: VRML), a ... Wallen, Ph.D. Chief Scientific Officer, Senior Vice ... will be joining its board of directors ... ,, "Bill brings more than 20 years ... biotechnology," said Gail Page, Vermillion Executive Chairperson. ...
(Date:12/14/2009)... -- The third edition of Infusion ... published by the Infusion Nurses Society (INS), includes ... Anthracyclines are a group of chemotherapy medications ... been used in the treatment of various types ... ,, According to the INS publication: "In September ...
(Date:12/14/2009)... SAN CARLOS, Calif., Dec. 14 Nektar ... Dennis Winger has been appointed to serve on ... highly-respected biopharmaceutical industry leader with over 35 years ... strategy. ,, "Dennis brings to Nektar extensive industry ... evolution," said Howard W. Robin, President and CEO ...
(Date:12/14/2009)... - Results From a Survey Conducted by UCB ... Industrialized Countries , , - A third ... impacts their enjoyment of the festive ... find shopping for gifts, preparing ... difficult to do, - ...
Breaking Biology Technology:Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4
... Assets -, LIONVILLE, Pa., Feb. 13 ... announced that it has concluded an,agreement with Nektar ... components for the Exubera(R) inhalable insulin device.,Production of ... Pfizer,Inc.,s decision to discontinue marketing the product, returning ...
... Approve Board Authority to Implement Reverse Stock Split and ... Total Shares and Authorized Shares, NEW HAVEN, Conn., Feb. ... a Special Meeting of,Stockholders was held at the Omni Hotel ... the meeting, shareholders voted to approve amendments to the,Company,s Restated ...
... Mountain Biosystems, Inc.(R),(RMBI), a Denver area biomedical ... of approximately $600,000 over two years from ... at the National Institutes of,Health (NIH) to ... influenza vaccination. In the event of a ...
Other Biology Technology:West Concludes Agreement with Nektar 2Vion Pharmaceuticals Holds Special Meeting of Stockholders 2Vion Pharmaceuticals Holds Special Meeting of Stockholders 3NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza 2
(Date:12/14/2009)... AlaskaScientists have identified a novel antifreeze molecule in a ... 100 degrees Fahrenheit. Unlike all previously described biological antifreezes ... little or no protein. It is composed of a ... new places within the cells of organisms. , ... this molecule is a whole new kind of antifreeze ...
(Date:12/14/2009)... transmitted by sneezing, touching, or for Tasmanian devils ... that may have driven the dinosaurs to extinction through ... a member of f1000 Biology, highlights the ,paleobiological detective ... One. This led them to deduce that a protozoan ... seen in many tyrannosaurid fossils. , The parasite,s modern-day ...
(Date:12/14/2009)... The most comprehensive study to date of the ... appendages may provide important clues to how similar regeneration ... the School of Science at Indiana University-Purdue University Indianapolis ... amputated limbs of axolotls, a type of salamander that ... any level of amputation, with the hope that this ...
Breaking Biology News(10 mins):Scientists isolate new antifreeze molecule in Alaska beetle 2IUPUI researchers tackle protein mechanisms behind limb regeneration 2EMD Serono Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application 62241 1EMD Serono Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application 62241 2EMD Serono Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application 62241 3More Seniors Considering Health Insurance Switch 62239 1More Seniors Considering Health Insurance Switch 62239 2Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR 28TM 29 14999 1Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR 28TM 29 14999 2
... of genomic rearrangement hotspots has its most recent addition ... the University of California San Diego. The study, ... that there are indeed rearrangement hotspots in the human ... a theory for analyzing complex rearrangements (including transpositions) which ...
... Cornell researchers have played a major role in an ... of genes of 12 closely related fruit fly species. ... from genetic adaptation to evolving immune systems -- the ... of each species., From the results of the research, ...
... other morphine-like substances known as opioids, which are released ... they may also protect you from heart attacks, according ... long been known that the so-called "runner,s high" is ... However, a UI study, which is published in the ...
Other Biology News:International team compares 12 fruit fly genomes 2International team compares 12 fruit fly genomes 3'Runner's high' may also strengthen hearts 2
PFM8 Antibody...
Goat polyclonal to DDDDK tag (FITC) ( Abpromise for all tested applications)....
Goat polyclonal to Nebraska Calf Diarrhea Virus (FITC) ( Abpromise for all tested applications). Antigen: Bovine (Nebraska Calf Diarrhea Virus)....
COMING SOON: Anti-Mouse CD205 (DEC-205),Clone NLDC-145, mAb...
Biology Products: